Actionable news
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta?


BOSTON (TheStreet) -- There is yet another twist in the crazy Duchenne muscular disease drug development story.

On Wednesday morning, the U.S. Food and Drug Administration confirmed Nov. 24 as the date for an advisory committee meeting to review BioMarin Pharmaceuticals' (BMRN - Get Report) Duchenne drug drisapersen. Notice of the meeting was posted in the Federal Register.

Where is the concurrent FDA advisory panel for Sarepta Therapeutics (SRPT - Get Report) and its Duchenne drug eteplirsen? Everyone expected FDA to schedule back-to-back panels on Nov. 23 and 24, but there is no discussion of a Sarepta meeting in Wednesday's Federal...